(6 days)
No
The description focuses on vibrating membrane technology for aerosolization and does not mention any AI or ML components or functionalities.
Yes
The device is a nebulizer system that aerosolizes medication for inhalation, which directly contributes to therapy.
No
The device is a nebulizer system intended for the aerosolization of medication, which is a therapeutic function, not a diagnostic one.
No
The device description explicitly states that the Altera Nebulizer System is a physical device consisting of a control unit and a nebulizer handset, employing vibrating membrane technology to aerosolize liquid medications. It is not solely software.
Based on the provided information, the Altera™ Nebulizer System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use is to aerosolize a specific medication (Cayston) for inhalation. This is a drug delivery system, not a device used to examine specimens derived from the human body for the purpose of providing information for diagnosis, monitoring, or treatment.
- Device Description: The description clearly states it's a nebulizer that aerosolizes liquid medications for inhalation therapy.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples, detecting analytes, or providing diagnostic information. The performance studies focus on the device's ability to aerosolize the drug effectively and safely.
Therefore, the Altera™ Nebulizer System falls under the category of a drug delivery device, not an IVD.
N/A
Intended Use / Indications for Use
The Altera™ Nebulizer System is intended specifically for the aerosolization of Cayston™ (aztreonam for inhalation solution) using vibrating membrane technology. The device is intended for adult and pediatric patients who have been prescribed Cayston, and may be used in hospitals, hospital-type facilities, nursing homes, sub-acute institutions and home environments.
Product codes (comma separated list FDA assigned to the subject device)
CAE, CAF
Device Description
The Altera™ Nebulizer System (hereinafter referred to as "Altera") is a drug specific version of the FDA-cleared eFlow Electronic Nebulizer, originally cleared in 510k No. K033833, and as modified in Special 510K No. K072670.
Both the Altera and the predicate eFlow are identical in purpose, function, core technology, basic design, materials and method of operation. They are single-patient use, reusable electronic nebulizers that employ micro-perforated vibrating membrane technology to aerosolize liquid medications. They are for adult and pediatric inhalation therapy in a home care, nursing home, sub-acute institution, or hospital environment. Both devices are hand-held and portable, consisting of a control, or base unit and a nebulizer handset, connected with a connection cord. Power input for both the Altera and the predicate eFlow is provided by either four AA batteries or a DC or AC adapter. Alternate power cords, plugs and adapters allow their use in any country.
However, unlike the predicate eFlow the Altera is drug-specific, intended for use only with aztreonam for inhalation solution.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
adult and pediatric patients
Intended User / Care Setting
hospitals, hospital-type facilities, nursing homes, sub-acute institutions and home environments.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Simulated Lifetime Testing - Aerosol Head
PARI conducted simulated lifetime testing of the series' Aerosol Heads 25, 30, 35 and 45. The results of the testing were that Aerosol Heads 25, 30, 35 and 45 met TOR and MMD specifications of the different head sizes following a simulated lifetime use.
Simulated Lifetime Testing - Validation of Cleaning and Disinfection Methods
Microbiological efficiency control tests were conducted in order to validate the nebulizer cleaning and disinfection methods in the IFU. Testing involved validation of both manual and automated cleaning methods, and a chemical disinfectant as well as a home sterilizer disinfection method. The testing concluded that the nebulizer can be cleaned and disinfected effectively by use of the methods stated in the IFU.
Aerosol Characterization Testing
PARI performed an aerosol characterization (particle size distribution) of the Altera in comparison with the predicate devices eFlow and LC Star. Testing was done by two methods: cascade impaction (Eight-Stage Anderson Cascade Impactor) and laser light scattering (Malvern MastersizerX). With respect to aerosol performance the Altera's MMAD. MMD and GSD is identical with or lower than the predicates eFlow and LC Star. The Altera's RF, TM and RM identical with or greater than the predicates eFlow and LC Star.
Drug-Specific Testing
The Altera's aerosol performance characteristics using aztreonam for inhalation solution were measured with the Andersen Cascade Impactor (ACI) method of eFlow Model 678G1002 as the aztreonam for inhalation solution commercial delivery system. These data appear in the AZLI New Drug Application (NDA) 50-814, and in 000,6004,PDR,01,02 eFlow® Electronic Nebulizer USA Model 678G 1002 "Product Description, Comparability Analysis with eFlow Model 78G 1004, and Discussion Regarding use as the Aztreonam Lysine for Inhalation
Airpath Testing
Although Altera is not compressor-driven, airpath testing was nonetheless conducted to ensure there are no environmental safety issues with the series involving volatile organic compounds (VOCs), emitted particulates and CO/CO2/Ozone gases.
EMC and electrical safety validations were not performed for this submission because the Altera's controller is identical to that cleared in 510K No. K072670. Previous testing established that, with respect to EMC and electrical safety in their intended operational environment, the control unit met the applicable requirements of: IEC 60601-1-2; CAN/CSA C22.2 NO 601.1-M90, and; UL 1431. Further, they have been subjected to IEC/EN/DIN EN 60068-2-3, 60068-2-6, 60068-2-14, 60068-2-29, and 60068-2-64 with respect to stress testing.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
K033833, K072670, K963924, K042991
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 868.5630 Nebulizer.
(a)
Identification. A nebulizer is a device intended to spray liquids in aerosol form into gases that are delivered directly to the patient for breathing. Heated, ultrasonic, gas, venturi, and refillable nebulizers are included in this generic type of device.(b)
Classification. Class II (performance standards).
0
K00380
SECTION 5: 510(K) SUMMARY
1. Submitter Information
| Name: | PARI Respiratory Equipment, Inc | FEB 2 2 2010 |
|---|---|---|
| Address: | 2943 Oak Lake Boulevard | |
| Midlothian, Virginia 23112-3998 | ||
| Phone: | 804-253-7274 x810 | |
| FAX: | 804-639-7244 | |
| Contact Name: | James L. McIntire Jr. | |
| Date Prepared: | February 9, 2010 | |
| Device Name: | ||
| Common Name: | Nebulizer | |
| Proprietary Name: | Altera™ Nebulizer System | |
| Classification Name: | Nebulizer (Direct Patient Interface) | |
| Regulation No.: | 868.5630 | |
| Class: | Class II | |
| Panel: | Anesthesiology | |
| Product Code: | CAE |
3. Device Description
The Altera™ Nebulizer System (hereinafter referred to as "Altera") is a drug specific version of the FDA-cleared eFlow Electronic Nebulizer, originally cleared in 510k No. K033833, and as modified in Special 510K No. K072670.
Both the Altera and the predicate eFlow are identical in purpose, function, core technology, basic design, materials and method of operation. They are single-patient use, reusable electronic nebulizers that employ micro-perforated vibrating membrane technology to aerosolize liquid medications. They are for adult and pediatric inhalation therapy in a home care, nursing home, sub-acute institution, or hospital environment. Both devices are hand-held and portable, consisting of a control, or base unit and a nebulizer handset, connected with a connection cord. Power input for both the Altera and the predicate eFlow is provided by either four AA batteries or a DC or AC adapter. Alternate power cords, plugs and adapters allow their use in any country.
However, unlike the predicate eFlow the Altera is drug-specific, intended for use only with aztreonam for inhalation solution.
1
4. Intended Use
The Altera™ Nebulizer System is intended specifically for the aerosolization of Cavston™ (aztreonam for inhalation solution) using vibrating membrane technology. The device is intended for adult and pediatric patients who have been prescribed Cayston, and may be used in hospitals, hospital-type facilities, nursing homes, sub-acute institutions and home environments..
5. Legally Marketed Predicate Devices
| Manufacturer | Device | 510(k) Number |
|---|---|---|
| PARI Innovative Manufacturers, Inc | eFlow Electronic Nebulizer | K033833, |
| K072670 | ||
| PARI Innovative Manufacturers, Inc | PARI LC Star Nebulizer | K963924 |
| Respironics® Inc. | I-Neb AAD System | K042991 |
6. Technological Characteristics Compared to Predicate Devices
The Altera, eFlow, LC Star and I-NEB AAD System are all nebulizers used to aerosolize medication for inhalation.
Altera and the predicate eFlow both use micro-perforated vibrating membrane technology to generate the aerosol. The predicate LC Star is a compressor-driven jet nebulizer, while the predicate I-neb® AAD® System uses vibrating mesh technology to generate its aerosol.
The Altera and the predicate I-neb AAD® System have similar intended uses in the restrictive application of the devices to medications that are specifically approved for them.
The Altera and eFlow make use of identical materials and design for the nebulizer, as compared to the LC Star, and also use a similar two valve system to provide breath enhanced aerosol delivery.
7. Summary of Performance Testing
Simulated Lifetime Testing - Aerosol Head થ.
PARI conducted simulated lifetime testing of the series' Aerosol Heads 25, 30, 35 and 45. The results of the testing were that Aerosol Heads 25, 30, 35 and 45 met TOR and MMD specifications of the different head sizes following a simulated lifetime use.
Simulated Lifetime Testing - Validation of Cleaning and Disinfection Methods b.
Microbiological efficiency control tests were conducted in order to validate the nebulizer cleaning and disinfection methods in the IFU. Testing involved validation of both manual and automated cleaning methods, and a chemical disinfectant as well as a home sterilizer disinfection method. The testing concluded that the nebulizer can be cleaned and disinfected effectively by use of the methods stated in the IFU.
Aerosol Characterization Testing c.
PARI performed an aerosol characterization (particle size distribution) of the Altera in comparison with the predicate devices eFlow and LC Star. Testing was done by two
2
methods: cascade impaction (Eight-Stage Anderson Cascade Impactor) and laser light scattering (Malvern MastersizerX). With respect to aerosol performance the Altera's MMAD. MMD and GSD is identical with or lower than the predicates eFlow and LC Star. The Altera's RF, TM and RM identical with or greater than the predicates eFlow and LC Star.
Drug-Specific Testing d.
The Altera's aerosol performance characteristics using aztreonam for inhalation solution were measured with the Andersen Cascade Impactor (ACI) method of eFlow Model 678G1002 as the aztreonam for inhalation solution commercial delivery system. These data appear in the AZLI New Drug Application (NDA) 50-814, and in 000,6004,PDR,01,02 eFlow® Electronic Nebulizer USA Model 678G 1002 "Product Description, Comparability Analysis with eFlow Model 78G 1004, and Discussion Regarding use as the Aztreonam Lysine for Inhalation
Airpath Testing e.
Although Altera is not compressor-driven, airpath testing was nonetheless conducted to ensure there are no environmental safety issues with the series involving volatile organic compounds (VOCs), emitted particulates and CO/CO2/Ozone gases.
EMC and electrical safety validations were not performed for this submission because the Altera's controller is identical to that cleared in 510K No. K072670. Previous testing established that, with respect to EMC and electrical safety in their intended operational environment, the control unit met the applicable requirements of: IEC 60601-1-2; CAN/CSA C22.2 NO 601.1-M90, and; UL 1431. Further, they have been subjected to IEC/EN/DIN EN 60068-2-3, 60068-2-6, 60068-2-14, 60068-2-29, and 60068-2-64 with respect to stress testing.
8. Conclusion
Based upon the above information the Altera Nebulizer System is substantially equivalent to the predicate devices, and raises no new issues of safety and effectiveness.
3
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized graphic of a caduceus, a symbol often associated with medicine and healthcare.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
Mr. James L. McIntire Jr. eFlow Regulatory PARI Respiratory Equipment, Incorporated 2943 Oak Lake Boulevard Midlothian, Virginia 23112
Re: K100380
Trade/Device Name: Altera™ Nebulizer System Regulation Number: 21 CFR 868.5630 Regulation Name: Nebulizer Regulatory Class: II Product Code: CAF Dated: February 9, 2010 Received: February 16, 2010
FEB 2 2 2010
Dear Mr. McIntire:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
4
Page 2 - Mr. McIntire
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to
http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers. International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor.You/Industry/default.htm.
Sincerely yours.
Anthom U.S.m
Anthony D. Watson, B.S., M.S., M.S., M.B.A. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Indications for Use
510(k) Number (if known):
Device Name: Altera™ Nebulizer System
Indications For Use: The Altera" Nebulizer System is intended specifically for the aerosolization of Cayston" (aztreonam for inhalation solution) using vibrating membrane technology. The device is intended for adult and pediatric patients who have been prescribed Cayston, and may be used in hospitals, hospital-type facilities, nursing homes, sub-acute institutions and home environments.
L. Schulte
(Division Sign-Off) Division of Anesthesiology, General Hospital Infection Control, Dental Devices
510(k) Number: 400380
Image /page/5/Picture/7 description: The image shows the words "Prescription Use" in bold font, followed by the text "(Part 21 CFR 801 Subpart D)" in a smaller font. There is a large "X" above a line to the right of the words "Prescription Use". The text indicates that the image is related to prescription drug regulations.
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)